Fluence

Canaccord Genuity is pleased to announce the completion of a placement of approximately 89.5 million new shares at an offer price of A$0.37 per share, raising gross proceeds of A$33.1 million on behalf of Fluence Corporation Limited (“Fluence” or the “Company”) (ASX.FLC). Canaccord Genuity acted as Lead Manager and Bookrunner for the transaction, which received strong support from institutional investors in North America, including a number of specialist sustainability funds, as well as continued support from other existing institutional and sophisticated investors based in Australia and the U.S.

Proceeds from the capital raise will be used for working capital to fund business growth in China for MABR and SUBRE based sales, partially fund of potential Build Own and Operate projects and for general working capital.

Fluence is a leader in decentralized water and wastewater treatment solutions with more than 7,000 references across 70 countries. The Company was established through the combination of independent water treatment solution providers Emefcy and RWL Water with the vision of becoming the leading global provider of fast-to-deploy, decentralized, and packaged water and wastewater treatment solutions. Fluence provides local, sustainable treatment and reuse solutions while empowering businesses and communities to make the most of their water resources. With core operations in North America, South America, the Middle East and Europe, Fluence is now focusing its sights on expanding into the vast Chinese market for rural wastewater treatment.

The Canaccord Genuity corporate finance deal team was led by Jeremy Dunlop and Dan Coyne, and was supported by Carl Henschke and Peter Cheetham in Sydney and Jennifer Pardi and Brian O’Connor in Boston. The Sydney and Boston Investment Banking and ECM teams worked closely together to successfully complete this cross-border transaction and deliver a positive outcome to our client. Significant support was provided by the global Sales team.